← Leaderboards
Paul R Skolnik
Tufts Medical Center
$6,410,809
Attributed
$6,410,809
Total exposure
18
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–10$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$4,689,108 · 17
CDC$1,721,701 · 1
By mechanism
R01$2,118,133 · 2
U65$1,721,701 · 1
T32$1,353,214 · 4
R21$859,489 · 2
P30$222,448 · 1
M01$135,824 · 8
Top collaborators
No co-investigators on record.
Most similar at Tufts Medical Center
Same institution · by research overlap
- Michael G Shlipak$18,418,069
- Sherwood L Gorbach$12,233,213
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHiv InfectionsClinical ResearchAids TherapyAlveolar MacrophagesAidsHuman Therapy EvaluationTumor Necrosis Factor AlphaEnzyme Linked Immunosorbent AssayImmunocytochemistryCytokineComorbidityHuman Immunodeficiency VirusFlow CytometryAntiaids AgentMitogen Activated Protein KinaseLungVirus LoadVirus ReplicationCytomegalovirusBiological Signal TransductionChemokineHuman TissueDrug Screening /Evaluation
Grant awards (39)
BU Clinical HIV/AIDS Research Training Program$149,664
T32 · FY2010 · AI · contact PI
PS04-064, HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION PROJECTS FOR CBO's$424,954
U65 · FY2009 · PS · contact PI
PS04-064, HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION PROJECTS FOR CBO's$427,185
U65 · FY2008 · PS · contact PI
PS04-064, HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION PROJECTS FOR CBO's$434,781
U65 · FY2007 · PS · contact PI
HIV INFECTED SUBJECTS COMPARING TENOFOVIR DISOPROXIL FUMARATE AND EMTRICITABINE$3,239
M01 · FY2007 · RR · contact PI
Modeling of Lung HIV Cytokine/Chemokine Networks$446,200
R01 · FY2006 · HL · contact PI
HUMAN IMMUNODEFICIENCY VIRUS(HIV)PREVENTION PROJECTS FOR CBO$434,781
U65 · FY2006 · PS · contact PI
Training Program in Host Pathogen Interactions$199,955
T32 · FY2006 · AI · contact PI
SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACOKINETICS IN HIV-1 INF MEN & WOMEN$2,186
M01 · FY2006 · RR · contact PI
HIV INFECTED SUBJECTS COMPARING TENOFOVIR DISOPROXIL FUMARATE AND EMTRICITABINE$1,091
M01 · FY2006 · RR · contact PI
INITIAL THERAPY FOR HIV-I INFECTION (ACTG A5142)$1,091
M01 · FY2006 · RR · contact PI
Modeling of Lung HIV Cytokine/Chemokine Networks$445,133
R01 · FY2005 · HL
Training Program in Host Pathogen Interactions$250,216
T32 · FY2005 · AI
Modeling of Lung HIV Cytokine/Chemokine Networks$45,000
R01 · FY2005 · HL
HUMAN IMMUNODEFICIENCY VIRUS(HIV)PREVENTION PROJECTS FOR CBO$0
U65 · FY2005 · PS
Modeling of Lung HIV Cytokine/Chemokine Networks$433,668
R01 · FY2004 · HL
Training Program in Host Pathogen Interactions$270,421
T32 · FY2004 · AI
Innate Immunity, HIV, and OIs: Role of TLRs in the Lung$228,302
R21 · FY2004 · AI
HUMAN IMMUNODEFICIENCY VIRUS(HIV)PREVENTION PROJECTS FOR CBO$0
U65 · FY2004 · PS
Modeling of Lung HIV Cytokine/Chemokine Networks$453,043
R01 · FY2003 · HL
Innate Immunity, HIV, and OIs: Role of TLRs in the Lung$228,687
R21 · FY2003 · AI
Lung TACE, TNFalpha &TNFR Regulation of HIV Replication$402,500
R21 · FY2002 · AI
Failing HAART--Do nutritional &clinical benefits persist$0
M01 · FY2002 · RR
CYTOKINES AND CYTOMEGALOVIRUS IN AIDS RELATED LUNG DISEASE$0
M01 · FY2002 · RR
ORALLY ADMINISTERED SP 303 FOR TREATMENT OF DIARRHEA IN AIDS PATIENTS$0
M01 · FY2002 · RR
HIV Pathogenesis Training Program$248,073
T32 · FY2001 · AI
CORE--IMMUNOVIROLOGY$129,540
P30 · FY2001 · AI
NEMCH CLINICAL RESEARCH ON AIDS TRAINING GRANT$122,776
T32 · FY2001 · AI
CYTOKINES AND CYTOMEGALOVIRUS IN AIDS RELATED LUNG DISEASE$0
M01 · FY2001 · RR
CORE--IMMUNOVIROLOGY$0
P30 · FY2001 · AI
Failing HAART--Do nutritional &clinical benefits persist$0
M01 · FY2001 · RR
ORALLY ADMINISTERED SP 303 FOR TREATMENT OF DIARRHEA IN AIDS PATIENTS$0
M01 · FY2001 · RR
CYTOKINES AND CMV IN AIDS RELATED LUNG DISEASE$295,089
R01 · FY2000 · HL
NEMCH CLINICAL RESEARCH ON AIDS TRAINING GRANT$112,109
T32 · FY2000 · AI
CORE--IMMUNOVIROLOGY$92,908
P30 · FY2000 · AI
ORALLY ADMINISTERED SP 303 FOR TREATMENT OF DIARRHEA IN AIDS PATIENTS$42,739
M01 · FY2000 · RR
SAFETY AND EFFICACY OF RS 79070 ORAL GANCICLOVIR VS IV GANCICLOVIR$42,739
M01 · FY2000 · RR
CYTOKINES AND CYTOMEGALOVIRUS IN AIDS RELATED LUNG DISEASE$42,739
M01 · FY2000 · RR
Failing HAART--Do nutritional &clinical benefits persist$0
M01 · FY2000 · RR